Drug profile · INN
vismodegib
ERIVEDGE
vismodegib (ERIVEDGE) is a smoothened homolog inhibitor. Associated with Hoffmann-La Roche. Route of administration: oral. Current US regulatory status: approved.
Drug details — vismodegib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
vismodegib (ERIVEDGE) is a smoothened homolog inhibitor. Associated with Hoffmann-La Roche. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Smoothened homolog inhibitor
Primary target: Protein smoothened
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Related & competitor drugs
Frequently asked questions
What is vismodegib?
vismodegib (ERIVEDGE) is a smoothened homolog inhibitor. Associated with Hoffmann-La Roche. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for vismodegib?
ERIVEDGE is a marketed brand name for vismodegib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of vismodegib?
vismodegib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.